Table 2.
The result of pathway analysis using Metaboanalyst3, for Alzheimer’s disease and also lavender-treated groups. The pathways with p-value<0.05 and impact value of more than 0 were selected.(*p<0.05, **p<0.01, ***p<0.001)
| Metabolic pathway category | Pathway name | Metabolite matches | p-value | Impact | ||
|---|---|---|---|---|---|---|
| AD | Treated | AD | Treated | |||
| Carbohydrate metabolism | ||||||
| pantothenate and CoA metabolism | Pantothenate, Valine | 0.011* | 0.009** | 0.02 | 0.02 | |
| TCA cycle | Succinate, Pyruvate | 0.02* | - | 0.097 | - | |
| glyoxilate and dicarboxylate metabolism | Glycolate, Citrate | - | 0.01* | - | 0.333 | |
| Amino acid metabolism | ||||||
| glycine, serine and threonine metabolism, | Serine, Choline, Glycine, Betaine, Pyruvate | 1.64E-5*** | - | 0.534 | - | |
| alanine, aspartate and glutamate metabolism | Alanine, Glutamine, Pyruvate, Succinate, Asparagine | 1.05E-4*** | 0.0014** | 0.149 | 0.149 | |
| Valine, leucine and isoleucine metabolism | Valine, Pyruvate, Isoleucine | 0.006** | - | 0.333 | - | |
| cysteine and methionine metabolism | Serine, Pyruvate, Methionine | 0.038* | 0.03* | 0.044 | 0.117 | |
| Genetic information processing | ||||||
| aminoacyl-tRNA biosynthesis | Glutamine, Glycine, Valine, Serine, Alanine, Asparagine, Methionine | 6.22E-4*** | 2.11E-5*** | 0.137 | 0.137 | |
| Energy metabolism | Methane metabolism | Glycine, Serine | 0.004** | - | 0.4 | - |